From Seattletimes
Shortly after suspending a major clinical trial because of serious illness in a patient, Targeted Genetics and federal regulators said Thursday that the person had died.

Whether it was the experimental arthritis drug being tested that caused the illness is not yet known. But the condition "was related in time to the receipt of a second injection of the product," the U.S. Food and Drug Administration said Thursday in a statement. The agency is investigating whether the illness was related to the treatment.

The FDA said it was informed about the death of the patient on Tuesday, the same day Targeted Genetics announced the interruption of the clinical trial in the wake of an "adverse event" for a patient.

"We are deeply saddened by the death of an individual enrolled in our clinical trial," Chief Executive H. Stewart Parker said Thursday in a statement.

Read More...